New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression

Journal of Pathology

Volumn 201, Issue 4, 2003, Pages 528-534

  Leeman, Matthew F ^a   Curran, Stephanie ^a   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Colorectal cancer; Matrix metalloproteinase; Tumour invasion

Indexed keywords

APOPTOSIS INDUCING FACTOR; BETA CATENIN; CELL ADHESION MOLECULE; CYTOSKELETON PROTEIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MATRILYSIN; MATRIX METALLOPROTEINASE; SCLEROPROTEIN;

CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

CELL ADHESION; CELL MOVEMENT; COLORECTAL NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; STROMAL CELLS;

EID: 1342333566     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1466     Document Type: Review

References (50)

1. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308.
2. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630.
3. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 2001; 195: 135-137.
4. Leeman MF, Curran S, Murray GI. The structure, regulation and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002; 37: 149-166.
5. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinases, inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2391.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 161-174.
7. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37-S43.
8. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999; 9: 1441-1447.
9. Vargo-Gogola T, Crawford HC, Gingleton B, Matrisian LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 2002; 408: 155-161.
10. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med 1996; 2: 461-462.
11. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase-13 is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002; 55: 758-762.
12. Yamamoto H, Itoh F, Hinoda Y, et al. Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin. Biochem Biophys Res Commun 1994; 201: 657-664.
13. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999; 107: 102-110.
14. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997; 94: 1402-1407.
15. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002; 122: 60-71.
16. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033-1038.
17. Crawford HC, Fingleton B, Gustavson MD, et al. The PEA3 sub-family of ets transcription factors synergize with betacatenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001; 21: 1370-1383.
18. Singh S, Barrett J, Sakata K, Tozer RG, Singh G. ETS proteins and MMPs: partners in invasion and metastasis. Curr Drug Targets 2002; 3: 359-367.
19. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-581.
20. Newell KJ, Matrisian LM, Driman DK. Matrilysin (matrix metalloproteinase-7) expression in ulcerative colitis-related tumorigenesis. Mol Carcinog 2002; 34: 59-63.
21. Ilyas M, Straub J, Tomlinson IPM, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335-351.
22. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteianse-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002; 21: 5861-5867.
23. Malhorta S, Newman E, Eisenberg D, et al. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer. Dis Colon Rectum 2002; 45: 537-543.
24. Uekita T, Itoh Y, Yana I, Ohno H, Seiki M. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 2001; 155: 1345-1356.
25. Nabeshima K, Inoue T, Shimao, Y, et al. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor. Cancer Res 2000; 60: 3364-3369.
26. Mori H, Tomari T, Koshikawa N, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002; 21: 3949-3959.
27. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001; 153: 893-904.
28. Lombard MA, Wallace TL, Kubicek MF, et al. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 1998; 58: 4001-4007.
29. Ilan N, Mohsenin A, Cheung L, Madri JA. PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J 2001; 15: 362-372.
30. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-624.
31. Giannelli G, Fransvea E, Marinosci F, et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002; 161: 183-193.
32. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-176.
33. Daemi N, Thomasset N, Lissitzky JC, et al. Anti-beta4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP-2 expression. Int J Cancer 2000; 85: 850-856.
34. Ratnikov BI, Rozanov DV, Postnova TI, et al. An alternative processing of integrin alphaV subunit in tumour cells by membrane type-1 matrix metalloproteinase. J Biol Chem 2002; 277: 7377-7385.
35. Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV, Strongin AY. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002; 277: 9749-9756.
36. Ebert EC. Mechanisms of colon cancer binding to substratum and cells. Digest Dis Sci 1996; 41: 1551-1556.
37. Agrez M, Gu X, Turton J, et al. The alphaVbeta6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer 1999; 81: 90-97.
38. Gu X, Niu J, Dorahy DJ, Scott R, Agrez MV. Integrin alpha(v)-beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells. Br J Cancer 2002; 87: 348-351.
39. Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002; 8: 144-148.
40. Hasegawa S, Koshikawa N, Momiyama N, et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998; 76: 812-816.
41. Brand K, Baker AH, Perez-Cantó A, et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinase-2 into the liver tissue. Cancer Res 2000; 60: 5723-5730.
42. Masuda H, Aoki H. Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer. Dis Colon Rectum 1999; 42: 393-397.
43. Ornstein DL, MacNab J, Cohn KH. Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer. Clin Exp Metastasis 1999; 17: 205-212.
44. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
45. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70: 561-573.
46. Kikuchi R, Noguchi T, Takeno S, Kubo N, Uchida Y. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 2000; 83: 215-218.
47. Ko K, Yazumi S, Yoshikawa K, et al. Activation of fibroblast-derived matrix metalloproteinase-2 by colon-cancer cells in non-contact co-cultures. Int J Cancer 2000; 87: 165-171.
48. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996; 74: 1161-1167.
49. Nielsen BS, Timshel S, Kjeldsen L, et al. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65: 57-62.
50. Segain JP, Harb J, Grégoire M, Meflah K, Menanteau J. Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumor but not from metastases. Cancer Res 1996; 56: 5506-5512.